What is ABVC's market cap?

$26.69M, based on the Nov 4 close of $1.00.

Does ABVC BioPharma pay a dividend?

No regular cash dividend has been paid in the last year.

How much of ABVC is sold short?

589.9K shares, 2.7% of float, as of Oct 15, 2026.

What sector is ABVC in?

Healthcare, in the Pharmaceuticals industry.

NASDAQ · ABVCHealthcarePharmaceuticals

ABVC BioPharma, Inc. Common Stock (ABVC)

$1.00+1.51%

Close Nov 4, 2026 · split-adjusted

Nov 2, 2026$0.98▼ 66.89% in range

Nov 3, 2025Low $0.71 · High $2.99Nov 2, 2026

What changed · written from our data

As of Nov 4, 2026

ABVC BioPharma closed at $1.00 on Nov 4, up 1.51%, 66.6% below its 52-week closing high. Volume of 41.7K shares was 0.91× its 20-day average (close to normal).

Split-adjusted performance: +3.1% over one month, -9.1% over six months, -66.2% over one year.

Short interest was 589.9K shares at the Oct 15 settlement, up 20.3% from the prior report (2.7% of float, 6.9 days to cover).

Market cap$26.7M26.7M shares

Revenue · quarter$0.00—

Diluted EPS$-0.03—

P/E · TTM—

Net margin—

Dividend yieldNone

52-week range0.71 – 2.99−66.6% from high

Volume41.7K0.91× 20-day avg

Volatility · 60d77.7%Annualised

Short % of float2.7%6.9 days to cover

Net cash$34.9KCash $94.4K

Next earnings—Not scheduled

Split-adjusted performance

1W −8.3%1M +3.1%3M −2.0%6M −9.1%YTD −53.1%1Y −66.2%3Y −17.4%5Y −95.9%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Pharmaceuticals

Percentile among 420 companies (100 = best)

6-month momentum65

Revenue growth—

Net margin—

Value (low P/E)—

Size24

Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.

Short interest

Details →

Shares short589.9K+20.3% vs prior

Days to cover6.9Settled Oct 15

% of float2.7%

Short vol. 10d19.4%of daily volume

Closest peers by size in Pharmaceuticals

Company	Price	Today	6M	Rev. growth	Net margin	P/E	Mkt cap
ABVCABVC BioPharma	$1.00	+1.51%	−9.1%	—	—	—	$26.7M
NXTCNextCure	$5.85	−1.02%	−45.4%	—	—	—	$26.8M	Compare
RNAZTransCode Therapeutics	$1.60	+1.91%	−78.7%	—	—	—	$27.1M	Compare
CELUCelularity	$0.8088	−1.02%	−13.0%	−5.3%	10.1%	—	$26.2M	Compare
AARDAardvark Therapeutics	$1.26	+2.44%	−78.6%	—	—	—	$27.6M	Compare
FLNAFilana Therapeutics	$0.5720	−3.75%	—	—	—	—	$27.6M	Compare
BCTXBriacell Therapeutics	$3.19	+5.98%	−23.1%	—	—	—	$27.9M	Compare
BYSIBeyondSpring	$0.6790	+9.34%	−56.2%	—	—	—	$27.9M	Compare
CPHIChina Pharma Holdings	$0.5875	−3.56%	+11.4%	−7.5%	−153.8%	—	$25.3M	Compare

News about ABVC BioPharma

All news →

No recent articles focused on ABVC BioPharma.

Quick answers

What does ABVC BioPharma do?: ABVC BioPharma Inc is a clinical stage biopharmaceutical company focused on development of new drugs and medical devices, all of which are derived from plants. It currently has six drugs and three medical devices in development.
What is ABVC's market cap?: $26.69M, based on the Nov 4 close of $1.00.
Does ABVC BioPharma pay a dividend?: No regular cash dividend has been paid in the last year.
How much of ABVC is sold short?: 589.9K shares, 2.7% of float, as of Oct 15, 2026.
What sector is ABVC in?: Healthcare, in the Pharmaceuticals industry.

About ABVC BioPharma

ABVC BioPharma Inc is a clinical stage biopharmaceutical company focused on development of new drugs and medical devices, all of which are derived from plants. It currently has six drugs and three medical devices in development. The firm specializes in botanically based solutions that deliver high efficacy with low toxicity for improved health outcomes. Its products include: Vitargus - ABV-1701, ABV-2001, ABV-2002, MDD ABV-1504, ADHD ABV-1505, ADHD ABV-1601, ABV-1501, ABV-1702, and ABV-1703.

HQ: Fremont, CA19 employeesListed Nov 9, 2004abvcpharma.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology